HOLLYWOOD, Fla. – Skin and nail diseases form a major proportion of podiatric practice but not a major proportion of training, according to a podiatrist speaking to an audience of dermatology clinicians about situations in which they could collaborate.
“I would probably put the estimate of training that involves dermatology at about 10%, but when you consider that 60% of our patient encounters involve skin and nails, there is a little bit of a disconnect,” William P. Scherer, DPM, MS, a podiatrist who practices in Delray Beach, Florida, said at the Society of Dermatology Physician Associates (SDPA) 24th Annual Fall Dermatology Conference.
The point of Scherer’s presentation at the meeting was that while toenails are a common interest for podiatrists and dermatology clinicians, training and focus of the two specialties differ.
Nail Cases Brought to Specialists Differ
Although essentially all toenail diseases can and are treated by both specialists, Scherer said some conditions — such as diabetic ulcers, heel pain, and bunions — more often find their way to podiatrists, while systemic inflammatory diseases such as psoriasis or dermatitis that affect the foot (or more specifically the nail) more often find their way to dermatology clinics.
Yet there is plenty of room to share expertise when a patient with a toenail condition goes to the closest clinician rather than the traditional choice, Scherer said. For example, he said he routinely refers psoriatic nails to a dermatology clinician once he makes the diagnosis, and he believes most of his colleagues do the same.
“Nail psoriasis is one of the conditions that I am very happy to refer. This is typically a whole-body problem, not just an issue for the lower extremity,” Scherer said.
He also said many podiatrists are happy to refer cases involving multiple sequential biopsies. While podiatrists can and do perform biopsies, they only average about three per year, whereas dermatologists do an average of about 500 per year, according to Medicare data Scherer cited.
The low relative rate at which podiatrists biopsy nails and skin does not equate to a difference in care quality but simply a difference in orientation, Scherer noted. However, such a difference might provide an opportunity for podiatrists and dermatology clinicians to collaborate when diagnosing disease and considering management after excision.
Conversely, he believes those who specialize in dermatology often fail to miss biomechanical etiologies for nail damage.
Microtrauma Plays a Role in Nail Disease Etiology
“Trauma resulting in toenail dystrophy is relatively common but underreported in the literature,” he said, warning that a substantial proportion of these cases involve microtrauma from poorly fitted shoes or other insults.
In many of these cases, damage to the nail provides the mechanism for fungal infection, but Scherer advised that the source of the microtrauma, whether it does or does not lead to infection, should be identified and treated.
In separating infection from the cause of the infection, Scherer pointed out that although all onychomycosis is onychodystrophy, not all onychodystrophy is onychomycosis. When the etiology of a case is unclear, he prefers to use the broader ICD code for onychodystrophy over onychomycosis.
The dermatology literature estimates that about 50% of onychodystrophy cases involve onychomycosis, but Scherer referred to a large 2024 retrospective cohort podiatry study with more than 96,000 nail specimens, which he coauthored. Based on confirmatory laboratory testing, which he called underutilized, the study found the overall positive rate was almost 60%.
For laboratory testing, he cautioned that KOH (potassium hydroxide) preparations are not adequately sensitive and have been largely replaced by the Periodic Acid-Schiff (PAS) stain, the Grocott-Gomori’s Methenamine Silver (GMS) stain, and the Fontana Masson (FM) stain, which are more reliable than KOH for positive or negative confirmation of a fungal infection. To reduce the risk of a false-negative result, he typically uses the PAS and GMS together.
For identification of the specific organism, he employs polymerase chain reaction (PCR), but the stains and PCR are generally complementary rather than alternative options, Scherer said.
Terbinafine Remains Common Nail Antifungal
For treatment, topical antifungals can be considered, but Scherer presented data indicating that mycologic cure with such topicals as efinaconazole in a 10% solution (54% cure) or tavaborole in a 5% solution (34% cure) is lower than the most commonly used oral medication, terbinafine 250 mg daily (70% cure). However, Scherer cautioned that terbinafine resistance is on the rise, and testing preemptively for terbinafine resistance with a PCR assay might be appropriate in some settings.
Nail disease and skin diseases can prove more complex than they appear at first evaluation, which is one of the reasons that Scherer advocated for podiatrists and dermatology clinicians to create a relationship for mutually beneficial management of difficult cases, or for referring cases outside their area of expertise.
The PA turnout for Scherer’s presentation was robust. One of those attending, Marze Lush, PA-C, Brevard Surgery and Cancer, Rockledge, Florida, said she see cases of nail diseases and appreciated the update on several aspects of care.
For nail diseases, “the idea of when to consider a referral is helpful,” Lush said.
Scherer reported a financial relationship with Bako Diagnostics. Lush reported no relevant financial relationships.
Ted Bosworth, a career medical writer based in New York City, has been covering advances in clinical medicine, including dermatology, for several decades.

